Cargando…

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Detalles Bibliográficos
Autores principales:	Frigault, Matthew J., Nikiforow, Sarah, Mansour, Michael K., Hu, Zhen-Huan, Horowitz, Mary M., Riches, Marcie L., Hematti, Peiman, Turtle, Cameron J., Zhang, Mei-Jie, Perales, Miguel-Angel, Pasquini, Marcelo C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. 2020
Materias:	Letters to Blood
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332891/ https://www.ncbi.nlm.nih.gov/pubmed/32457999 http://dx.doi.org/10.1182/blood.2020006216

Ejemplares similares

ICANS prophylaxis: potentially transformative but elusive
por: Dowling, Mark R., et al.
Publicado: (2023)

CD7 CAR: sword and shield
por: Velasquez, M. Paulina, et al.
Publicado: (2022)

Buckling up against COVID-19 after CAR T-cell therapy
por: Auletta, Jeffery J.
Publicado: (2022)

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy
por: Dhakal, Binod, et al.
Publicado: (2021)

Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19
por: Miller, Peter G., et al.
Publicado: (2022)

Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients
por: Oh, Bernice Ling Zhi, et al.
Publicado: (2022)

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

This CAR won’t start: predicting nonresponse in ALL
por: Webster, Jonathan A., et al.
Publicado: (2023)

On a collision course: SARS-CoV-2 variants and CAR T cells
por: Auletta, Jeffery J.
Publicado: (2023)

Comorbidities in DLBCL: too "Severe4" CAR-T therapy?
por: Qualls, David, et al.
Publicado: (2023)

RACGAP1 variants in a sporadic case of CDA III implicate the dysfunction of centralspindlin as the basis of the disease
por: Wontakal, Sandeep N., et al.
Publicado: (2022)

Prediction paradigm involving time series applied to total blood issues data from England
por: Nandi, Anita K., et al.
Publicado: (2020)

New blood donors in times of crisis: Increased donation willingness, particularly among people at high risk for attracting SARS‐CoV‐2
por: Spekman, Marloes L. C., et al.
Publicado: (2021)

FinDonor 10 000 study: a cohort to identify iron depletion and factors affecting it in Finnish blood donors
por: Lobier, Muriel, et al.
Publicado: (2019)

Determinants of blood donation willingness in the European Union: a cross‐country perspective on perceived transfusion safety, concerns, and incentives
por: Huis in ‘t Veld, Elisabeth M.J., et al.
Publicado: (2019)

Anticoagulation in hospitalized patients with COVID-19
por: Baumann Kreuziger, Lisa, et al.
Publicado: (2022)

Personalized collection of plasma from healthy donors: A randomized controlled trial of a novel technology‐enabled nomogram
por: Hartmann, Jan, et al.
Publicado: (2021)

Identification and Re-consent of Existing Cord Blood Donors for Creation of Induced Pluripotent Stem Cell Lines for Potential Clinical Applications
por: Abberton, Keren M, et al.
Publicado: (2022)

Ensuring HLA‐matched platelet support requires an ethnic diverse donor population
por: Kreuger, Aukje L., et al.
Publicado: (2020)

Systematic review protocol: an assessment of the post-approval challenges of autologous CAR-T therapy delivery
por: Lam, Ching, et al.
Publicado: (2019)

Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies
por: Davis, James A., et al.
Publicado: (2023)

Nanofiltration as a robust method contributing to viral safety of plasma‐derived therapeutics: 20 yearsʼ experience of the plasma protein manufacturers
por: Roth, Nathan J., et al.
Publicado: (2020)

Surrogate test performance for SARS‐CoV‐2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?
por: Wendel, Silvano, et al.
Publicado: (2021)

Performance characteristics of a novel blood bag in-line closure device and subsequent product quality assessment
por: Serrano, Katherine, et al.
Publicado: (2010)

Failure of self-disclosure of deferrable risk behaviors associated with transfusion-transmissible infections in blood donors
por: Wong, Horas Tze Hoo, et al.
Publicado: (2015)

Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone
por: Tedder, Richard S., et al.
Publicado: (2018)

Estimation of the number of blood donors during the COVID‐19 incubation period across China and analysis of prevention and control measures for blood transfusion transmission
por: Yuan, Zhaohu, et al.
Publicado: (2020)

Deferral rate variability in blood donor eligibility assessment
por: de Kort, Wim, et al.
Publicado: (2018)

First results of a ferritin‐based blood donor deferral policy in the Netherlands
por: Vinkenoog, Marieke, et al.
Publicado: (2020)

Do deferred donors continue their donations? A large‐scale register study on whole blood donor return in the Netherlands
por: Spekman, Marloes L.C., et al.
Publicado: (2019)

Frequent platelet donation is associated with lymphopenia and risk of infections: A nationwide cohort study
por: Zhao, Jingcheng, et al.
Publicado: (2020)

Whole blood donor behavior and availability after deferral: Consequences of a new ferritin monitoring policy
por: Spekman, Marloes L.C., et al.
Publicado: (2020)

Barriers to blood donation on social media: An analysis of Facebook and Twitter posts
por: Ramondt, Steven, et al.
Publicado: (2020)

Risk of hematological malignancy in blood donors: A nationwide cohort study
por: Zhao, Jingcheng, et al.
Publicado: (2020)

Assessment of serological assays for identifying high titer convalescent plasma
por: Farnsworth, Christopher W., et al.
Publicado: (2021)

Staff perspectives on barriers and enablers to implementing alternative source plasma eligibility criteria for gay, bisexual, and other men who have sex with men
por: Castillo, Gisell, et al.
Publicado: (2022)

How to increase first‐time donors' returns? The postdonation letter's content can make a difference
por: Moussaoui, Lisa S., et al.
Publicado: (2022)

Sexual risk behavior questions: Understanding and mitigating donor discomfort
por: Haw, Jennie, et al.
Publicado: (2021)

Mitigating the risk of transfusion‐transmitted infections with vector‐borne agents solely by means of pathogen reduction
por: Stramer, Susan L., et al.
Publicado: (2022)

Plasmavigilance—Adverse events among US Source plasma donors
por: Schreiber, George B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e3gh6m08hem5m4c762una26ji3